comprehensive -WSS

comprehensive

author：explore 2025-09-29 12:30:34 - browse：57257

Boston Scientific headquarters -- Health coverage from STAT — Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Readout Newsletter: Geron, Novo Nordisk, WuXi updates

WSS

Leading voice in opioid treatment defends methadone clinic system

5 to watch: Tech startups trying to solve health care's staffing crisis

Colonoscopy prep: Liquid

CVS Caremark has created a new ploy: the drug ‘rebate credit’

The world needs the new pandemic treaty

Why some fertility treatments produce more boy babies

focus

comprehensive

focus

Duchenne breakthrough therapy leaves behind pioneering families

Why we need mandatory labeling of GMO products

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Lawsuit challenges CMS nursing home minimum staffing rule

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Unmasking the 'centricity' illusion in clinical trials

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Stroke rates rising, especially in working

Anesthesiologist group: stop taking Ozempic before surgery

Orchard's therapy for neuron disease in children wins FDA approval

focus

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Ozempic cut risk of death in diabetes patients with chronic kidney disease

Congress: Prevent baby formula shortages by passing a new bill

Methadone treatment changes are coming. Do they go far enough?

Why some fertility treatments produce more boy babies

U.S. death rates show how politics are affecting public health

hotspot

Wikipedia

focus

hotspot